Register
  • Community
    • Physicians
    • Editors
    • Experts
    • Code of conduct
    • Blog
    • Terms of Use
    • Privacy Policy
    • Sitemap
  • Company
    • About
    • Publications
    • Press
    • Careers
  • Programs
    • Journal Club
    • Targeted Topic
    • Clinical Trial
    • Tumor Board
  • Contact Us
  • Sign in

Medical Oncology

GCA   

Questions discussed in this category


Is IL-6 inhibition an option in patients who are going to be rechallenged with checkpoint inhibitors after previously developing ICI-mediated temporal arteritis?
Would the checkpoint inhibitor still work if blocking only that portion of the inflammatory cascade as opposed to more global blockade with steroids?
2 Answers available
13272


Papers discussed in this category


Eur J Cancer, 2021 Sep 15
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.

Thorac Cancer, 2020 Feb 11
The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).

Related Topics in Medical Oncology

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Cancers
  • Palliation
  • Neuro-Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers

Copyright © 2023 theMednet
All Rights Reserved.